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Abstract
Significance: Diabetes and other diseases that comprise the metabolic syndrome have reached epidemic pro-
portions. Diabetic peripheral neuropathy (DPN) is the most prevalent complication of diabetes, affecting*50%
of diabetic patients. Characterized by chronic pain or loss of sensation, recurrent foot ulcerations, and risk for
amputation, DPN is associated with significant morbidity and mortality. Mechanisms underlying DPN patho-
genesis are complex and not well understood, and no effective treatments are available. Thus, an improved
understanding of DPN pathogenesis is critical for the development of successful therapeutic options. Recent
Advances: Recent research implicates endoplasmic reticulum (ER) stress as a novel mechanism in the onset and
progression of DPN. ER stress activates the unfolded protein response (UPR), a well-orchestrated signaling
cascade responsible for relieving stress and restoring normal ER function. Critical Issues: During times of
extreme or chronic stress, such as that associated with diabetes, the UPR may be insufficient to alleviate ER
stress, resulting in apoptosis. Here, we discuss the potential role of ER stress in DPN, as well as evidence
demonstrating how ER stress intersects with pathways involved in DPN development and progression. An
improved understanding of how ER stress contributes to peripheral nerve dysfunction in diabetes will provide
important insight into DPN pathogenesis. Future Directions: Future studies aimed at gaining the necessary
insight into ER stress in DPN pathogenesis will ultimately facilitate the development of novel therapies.
Antioxid. Redox Signal. 21, 621–633.
Introduction
D iseases that comprise the metabolic syndrome, in-cluding obesity, atherosclerosis, and diabetes mellitus,
have reached epidemic proportions. In 2012, the International
Diabetes Federation reported that over 370 million people
worldwide have diabetes (38). In the US, 1.9 million new
diabetes cases were diagnosed in 2010, adding to the existing
cases for a total of 25 million Americans, or over 8% of the
population (12). A further 33% of the US population is af-
fected by prediabetes, a condition characterized by elevated
glucose levels and impaired glucose tolerance, and associated
with a high risk of developing diabetes (15, 25).
Diabetes is a complex metabolic disorder affecting car-
bohydrate, lipid, protein, and electrolyte metabolism. Type 1
diabetes is due to impaired insulin signaling resulting from
pancreatic islet cell death, while type 2 diabetes is due to
insulin resistance in metabolically active tissues. Chronic
hyperglycemia in diabetes invokes the onset of macro-
vascular (heart disease, stroke, and peripheral arterial dis-
ease) and microvascular (nephropathy, retinopathy, and
neuropathy) complications. Diabetic peripheral neuropathy
(DPN) is the most prevalent microvascular complication,
affecting*50% of diabetic patients (19). The consequences
of DPN include chronic pain or loss of sensation, recurrent
foot ulcerations, and amputation (20). Mechanisms under-
lying the pathogenesis of DPN are complex and despite over
30 years of intensive research, no mechanism-based treat-
ment has proved effective in the treatment of DPN in man
(20, 96). An improved understanding of DPN pathogenesis is
critical for the development of successful therapeutic options.
Recent research implicates endoplasmic reticulum (ER)
stress as a novel mechanism in the onset and progression of
DPN (56, 57).
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ER stress is associated with the development of various
diseases, including neurodegenerative disorders (53) and
more recently the metabolic syndrome (3, 68, 76, 80, 105). In
this review, we summarize evidence supporting the potential
role of ER stress in the pathogenesis of DPN. We first in-
troduce the ER stress response and then present evidence of
ER stress in DPN. Finally, we discuss the important inter-
section of ER stress pathways with other established signal-
ing mechanisms associated with peripheral nerve injury in
DPN. Understanding how ER stress contributes to peripheral
nerve dysfunction in diabetes will provide important insight into
DPN pathogenesis and may identify novel therapeutic targets.
The ER Stress Response
The ER is a membranous network that extends from the
nuclear envelope toward the periphery of the cell. It is re-
quired for protein packaging and lipid biosynthesis, and acts as
an intracellular calcium store and as a sensor of cellular stress.
All secreted and membrane proteins must undergo specific
post-translational modifications and appropriate protein fold-
ing within the ER before they are fully functional and targeted
to their final destination. The ER has an intricate quality
control system to ensure accuracy of protein folding and
post-translational modifications, with the capacity to adapt to
homeostatic disturbances caused during periods of cellular
stress or at times when increased demands on protein pro-
duction occur. Pathological cellular stressors that disrupt ER
homeostasis include increases in unsaturated fatty acids or
cholesterol, altered redox status, nutrient deprivation, elevated
glucose, and perturbation of calcium homeostasis. These
stressors result in the accumulation of unfolded or misfolded
proteins within the luminal space of the ER, resulting in
ER stress and activation of the unfolded protein response
(UPR), a well-orchestrated signaling cascade responsible for
relieving stress and restoring normal ER function (17). This is
accomplished by (i) attenuating protein translation, (ii) upre-
gulating the synthesis of chaperones and enzymes that assist in
protein folding, and (iii) promoting protein degradation via
ER-associated protein degradation (ERAD) (78).
Responding to stress: the UPR
The distinct signaling pathways of the UPR are mediated by
three sensors that detect disturbances in the luminal environ-
ment of the ER: protein kinase-R-like ER kinase (PERK),
activating transcription factor 6 (ATF6), and inositol-requiring
enzyme 1a (IRE1a) (Fig. 1). Under native conditions, the
chaperone binding immunoglobulin protein (BiP), also known
as glucose regulating protein (GRP)78, is bound to each sensor
to prevent their activity. During periods of ER stress, however,
BiP dissociates from the sensors and preferentially binds to
misfolded or unassembled proteins within the ER, resulting in
the activation of the UPR (6, 58, 79). Dissociation of BiP from
PERK results in dimerization and autophosphorylation of the
kinase to activate the PERK pathway and decrease protein
influx into the ER. This translational attenuation is achieved by
PERK-mediated phosphorylation of eukaryotic initiation fac-
tor 2a (eIF2a) that in turn blocks the guanine nucleotide ex-
change activity of eIF2B that is required for eIF2a cycling and
continued protein synthesis (32, 44). Repression of global
protein synthesis resulting from limited eIF2a activity results
in favored translation of mRNAs, including activating tran-
scription factor 4 (Atf4) (104). Translocation of ATF4 to the
nucleus upregulates expression of proteins and chaperones
required to restore ER homeostasis (33). Dissociation of BiP
from the transcription factor ATF6 results in translocation of
ATF6 to the Golgi apparatus where it undergoes sequential
proteolysis by site 1 and site 2 proteases. The cytosolic fragment
of ATF6 translocates to the nucleus where it induces tran-
scription of molecular chaperone proteins, similar to ATF4 (34,
77). Finally, dissociation of BiP from IRE1a results in IRE1a
dimerization and autophosphorylation (109). Following autop-
hosphorylation, IRE1a endoribonuclease activity cleaves X-box
binding protein 1 (Xbp1) mRNA to remove a 26-nucleotide
intron. Spliced X-box binding protein 1 (sXbp1) is translated
and in turn XBP1 translocates to the nucleus to initiate tran-
scription of chaperone proteins and proteins involved in ERAD.
Together, these adaptive mechanisms of the UPR function to
attenuate mild to moderate ER stress to restore normal ER
function (78).
Responding to stress: apoptosis
During times of extreme or chronic stress, the capacity of
the UPR is overwhelmed, and the resulting failure to alleviate
ER stress triggers apoptotic processes (Fig. 2) (28). In addi-
tion to splicing Xbp1 mRNA, activated IRE1a is capable of
triggering cell death via its association with tumor necrosis
factor receptor-associated factor 2 (TRAF2) and apoptosis
signal-regulating kinase 1 (ASK1). During ER stress, the
adapter protein TRAF2 is recruited to the kinase domain of
IRE1a, followed by ASK1, and the formation of the IRE1a/
TRAF2/ASK1 heterooligomeric complex then recruits c-Jun-
N-terminal kinase ( JNK) and activates the JNK signaling
pathway, promoting the establishment of a proapoptotic en-
vironment (93). The PERK-mediated branch of the UPR also
contributes to stress-induced apoptosis. PERK activation and
phosphorylation of eIF2a leads to upregulation of Atf4,
which subsequently induces the transcription of C/EBP ho-
mologous protein (Chop). CHOP is ubiquitously expressed at
low levels during normal cellular homeostasis; however,
persistent ER stress leads to robust CHOP expression.
Chop - / - cells are protected from ER stress-induced apo-
ptosis (113), and CHOP has been associated with inherited
demyelinating disorders, including Charcot–Marie–Tooth
1B disease (16, 73), further highlighting the significance of
this pathway. CHOP contributes to apoptosis via upregula-
tion of ER oxidase 1a (Ero1a), which subsequently activates
the ER calcium channel inositol 1,4,5-triphosphate (IP3) to
trigger the release of calcium stores into the cytosol (47). This
ER stress-induced release of calcium results in inner mito-
chondrial membrane depolarization, cytochrome c release,
and initiation of cell death processes (90). CHOP also acti-
vates growth arrest and DNA damage 34 (GADD34), which
dephosphorylates eIF2a, thereby promoting the recovery of
protein synthesis that was repressed by PERK (16, 59). Fi-
nally, in mice, the UPR-induced activation of apoptosis is
further complimented by cleavage of procaspase-12 within
the ER to alternatively initiate the caspase signaling cascade
(66, 88).
ER Stress in Disease
Dysregulated ER stress responses have been implicated in
various degenerative disorders, such as Parkinson’s disease,
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Alzheimer’s disease, multiple sclerosis, Charcot–Marie–
Tooth 1B, and amyotrophic lateral sclerosis (53, 73, 80,
83). In recent years, a large body of literature has also been
documented linking ER stress to diseases of the metabolic
syndrome, thus supporting the premise that ER stress may
be a critical player in DPN pathogenesis (Table 1) (3, 68,
76, 105).
ER stress in the metabolic syndrome
Diseases of the metabolic syndrome include obesity, ath-
erosclerosis, and diabetes. Obesity-induced ER stress has
been identified in mice with diet-induced obesity, a model of
prediabetes, and in type 2 diabetes leptin-deficient ob/ob
mice, as evidenced by elevated levels of phosphorylated
PERK and eIF2a in liver and adipose tissue compared with
lean controls (68). This association was further confirmed in
man. Reductions in Bip and sXbp1 as well as increases in
phosphorylated eIF2a and JNK are present in adipose tissue
of obese patients (29), and increased eIF2a phosphorylation,
ATF4, and CHOP are evident in liver tissue of obese patients
(74). Increased ER stress is also manifest in diabetic patho-
physiology. Pancreatic b cells undergo UPR-induced apo-
ptosis due to sustained insulin signaling (21), UPR-dependent
insulin resistance in liver and muscle is associated with ac-
tivation of the JNK signaling pathway (24), and diabetes-
induced ER stress has been linked to diabetic nephropathy,
retinopathy, and cognitive decline (14, 80, 89, 112). More
recently, however, evidence has arisen implicating a role for
ER stress in peripheral nerve injury and DPN (56, 57).
ER stress in DPN
DPN is primarily a sensory polyneuropathy. Despite being
described as the most common and devastating complication
associated with diabetes, there are no effective therapies. The
main reason for lack of treatment options is an incomplete
understanding of disease pathogenesis. DPN development
and progression occur within the heterogeneous environment
of the peripheral nerve and involve a complex interplay
FIG. 1. The UPR signaling pathway. During normal cellular homeostasis, the ER chaperone BiP, also known as GRP78,
is associated with the ER transmembrane sensors PERK, eIF2a, and ATF6. The ER stress response is activated when BiP
dissociates from the ER stress sensors and binds to misfolded proteins, thus activating the three arms of the UPR.
Dimerization and autophosphorylation of PERK phosphorylates eIF2a, which halts protein synthesis and activates ATF4
translocation to the nucleus, where ATF4 initiates the transcription of genes involved in restoring homeostasis. IRE1a
autophosphorylation promotes the splicing of Xbp1. Once spliced and activated, sXBP1 translocates to the nucleus where it
initiates transcription of genes leading to the expression of molecular chaperones and components of the ERAD system.
Following dissociation from BiP, ATF6 translocates to the Golgi apparatus where it is cleaved by specific proteases, after
which, fragmented ATF6 moves to the nucleus and initiates transcription of molecular chaperone proteins. Together, these
pathways alleviate stress and restore homeostasis by halting protein translation, upregulating synthesis of molecular
chaperones, and activating ERAD. ATF4, activating transcription factor 4; ATF6, activating transcription factor 6; BiP,
binding immunoglobulin protein; eIF2a, eukaryotic initiation factor 2a; ER, endoplasmic reticulum; ERAD, ER-associated
protein degradation; GRP, glucose regulating protein; IRE1a, inositol-requiring enzyme 1a; PERK, protein kinase-R-like
ER kinase; XBP1, X-box binding protein 1; UPR, unfolded protein response. To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/ars
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between the nerve and surrounding cells and tissues. A de-
creased blood flow to the nerves (108), hyperglycemia (35,
99, 101), dyslipidemia (98, 99), and a lack of insulin sig-
naling (42) contribute to DPN pathogenesis. These factors
induce multiple pathogenic processes, such as low-grade
inflammation, elevated sorbitol aldose reductase signaling,
protein kinase C activation, advanced glycated end products,
oxidative stress, and mitochondrial dysfunction (96), which
culminate in the physiologic and morphologic changes as-
sociated with DPN.
A role of ER stress in DPN is being increasingly consid-
ered based on in vivo evidence supporting ER stress in-
volvement in the initiation and progression of DPN in both
type 1 and type 2 diabetic rodent models. Furthermore,
studies using ER chaperone proteins, which assist protein
folding in the ER by preventing newly synthesized poly-
peptide chains and assembled subunits from aggregating
into nonfunctional structures, is an emerging therapeutic
approach aimed at restoring ER function (22). Oral ad-
ministration of trimethylamine oxide (TMAO), a chemical
chaperone known to alleviate ER stress, to Zucker fatty (fa/
fa) rats decreased protein expression of BiP/GRP78 in the
sciatic nerve, and improved nerve conduction velocities and
behavioral responses to mechanical and thermal stimuli (56).
C57B6 mice fed a high-fat diet (HFD) also displayed an
improved neuronal phenotype when treated with salubrinal, a
compound that enhances eIF2a phosphorylation (56). Neu-
ropathy severity was also attenuated in streptozotocin (STZ)-
treated rats treated with TMAO (57). Finally, C57B6
Chop - / - mice injected with STZ displayed improved nerve
function and increased expression of the folding proteins BiP/
GRP78 and GRP94 in peripheral nerves compared with wild-
type STZ-injected mice, further suggesting a role for ER
signaling in DPN development (57). Together, these data
support a link between ER stress and DPN, as restoration of
ER function by administration of chemical chaperones or ER
stress inhibitors alleviates ER stress and improves peripheral
nerve function (56, 57).
Although these studies confirm the role of ER stress in
DPN, certain considerations must be made when evaluating
outcomes following systemic administration of chemical
chaperones. As both hyperglycemia and dyslipidemia are
known contributors to DPN (10, 96, 98), improved neuronal
phenotypes could be attributed to enhanced UPR function in
pancreatic b cells rather than direct effects on the UPR in the
peripheral nerve. Administration of the chemical chaperone
phenyl butyric acid (PBA) or overexpression of oxygen
regulated protein 150 (ORP150) improves pancreatic b cell
function and enhances insulin secretion, which in turn im-
proves the metabolic profile of the animal (67, 69). Similarly,
insulin sensitivity in adipose and hepatic tissue may be
restored following chaperone treatment (24). This must also
be considered in DPN studies. TMAO treatment in Zucker
fa/fa rats improved blood glucose and triglyceride levels,
and impaired glucose tolerance was attenuated in high
fat-fed mice treated with salubrinal (56). Thus, systemic
FIG. 2. ER stress-associated apoptosis. Under conditions of unresolvable ER stress, apoptotic pathways are activated.
IRE1a forms a multioligomer complex with TRAF2 and ASK1, and in turn recruits and activates JNK, which promotes cell
death by establishing a proapoptotic environment. The PERK/eIF2a pathway is also capable of activating apoptosis via
ATF4-mediated upregulation of CHOP, which activates expression of proapoptotic genes and downregulates the expression
of antiapoptotic genes. CHOP also induces the expression of ERO1a, which activates the ER calcium release channel, IP3,
resulting in increased cytosolic calcium that triggers mitochondrial-associated cell death. Alternatively, activation and
cleavage of ER-bound caspase-12 can trigger apoptosis via UPR-independent mechanisms. ASK1, apoptosis signal-regulating
kinase 1; CHOP, C/EBP homologous protein; ERO1a=ER oxidase 1a; IP3, inositol 1,4,5-triphosphate; JNK, c-Jun-N-
terminal kinase; TRAF2, tumor necrosis factor receptor-associated factor 2. To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/ars
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administration or overexpression of chaperones may mask
the beneficial effects on the nerve by indirectly improving the
metabolic profile. To circumvent these issues, direct neuronal
delivery of chaperones without impacting systemic glycemia
may be warranted to elucidate the role of ER stress on nerve
function in DPN. However, TMAO treatment in STZ-
injected rats improved DPN phenotypes despite maintained
hyperglycemia (57), suggesting that therapies targeting ER
stress responses may have direct efficacy in the peripheral
nerve.
Table 1. ER Stress in Diseases Related to the Metabolic Syndrome
Tissue/cell Disease model ER stress response Ref.
Obesity/atherosclerosis
Liver Prediabetic HFD-fed
mice; type 2
diabetic ob/ob mice
ER stress promotes JNK-induced phosphorylation
of IRS1 and a resulting decrease in insulin
gene expression
(68)
HFD-fed Lcat - /- mice Cholesterol contributes to diet-induced obesity
and insulin resistance through an ER
stress-mediated pathway
(31, 49)
Macrophage Mouse peritoneal
macrophages
Cholesterol loading depletes calcium stores and
activates ER-dependent apoptosis
(23, 74)
Adipose
tissue
HFD-fed mice;
3T3-L1 preadipocytes
Hypoxia increases the expression of Bip and
Chop mRNA
(36)
Diabetes
Pancreas INS-1 and rat
pancreatic islet cells
High glucose treatment increases Chop and Bip
mRNA expression
(29, 103)
Pancreatic b cells Chronic high glucose exposure causes ER stress,
hyperactivation of IRE1a, and suppression of insulin
expression; pancreatic islets show increased IRE1a
phosphorylation and increased sXbp1
mRNA expression
(54)
db/db pancreatic islets; type 2
diabetic patient pancreatic
sections; insulin secreting
MIN6 cells
ER stress identified in palmitate-treated MIN6 cells
and islets from db/db mice; elevated BiP and CHOP
are evident in pancreatic sections from
type 2 diabetic patients
(46)
Diabetic complications
Kidney Type 1 diabetic STZ rats Elevated BiP, CHOP, JNK, and caspase-12 is
evident in kidney homogenates
(55)
Human diabetic
nephropathy kidney
biopsies; renal
epithelial cells
Diabetic nephropathy patients exhibit increased
BiP and sXbp1; hyperglycemia induces Xbp1
and Bip in renal epithelial cells
(52)
Cultured murine podocytes Palmitate-induced lipotoxicity increased BIP
and CHOP levels, and decreased levels of
the antiapoptotic protein Bcl-2
(89)
Eye Akita mice; oxygen-induced
retinopathy mice
Increased levels of Bip, mRNA; eIF2a, and ATF4
protein present in mouse retina; tunicamycin
increased BiP and ATF4 in mouse retina
(48)
Type 1 diabetic STZ mice; rat
Muller retinal cells
STZ-treated mice exhibit elevated ATF4 in Muller
cells of the retina; high glucose induces ATF4 in
cultured rat retinal Muller cells
(112)
Nerve Immortalized Schwann cells Palmitate-induced lipotoxicity upregulates Chop,
Bip, and Xbp1; ER stress response is magnified
with increasing levels of glucose
(70)
Zucker fa/fa rats Elevated BiP and GRP94 protein expression
in sciatic nerve
(56)
Type 1 diabetic STZ rats;
STZ-treated ChoP - /- mice
Phosphorylated PERK, eIF2a, IRE1a, BiP,
and ERO1a identified in sciatic nerve, and
increased CHOP, ERO1a, and BiP identified
in spinal cord of STZ-treated rats; Chop
knockout in STZ diabetic mice
improves DPN phenotypes
(57)
ATF4, activating transcription factor 4; BiP, binding immunoglobulin protein; CHOP, C/EBP homologous protein; DPN, diabetic
peripheral neuropathy; eIF2a, eukaryotic initiation factor 2a; ER, endoplasmic reticulum; ERO1a, ER oxidase 1a; GRP, glucose regulating
protein; HFD, high-fat diet; IRE1a, inositol-requiring enzyme 1a; IRS1, insulin receptor substrate 1; JNK, c-Jun-N-terminal kinase; PERK,
protein kinase-R-like ER kinase; STZ, streptozotocin; XBP1, X-box binding protein 1; sXBP1, spliced X-box binding protein 1.
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Molecular Mechanisms of ER Stress and DPN
Although the previous studies validate the contention that
ER stress is present in DPN, mechanistic studies are required
to elucidate the involvement and implications of ER stress in
DPN development and progression. Given the heterogeneous
environment of the peripheral nerve, vascular endothelial
cells, macrophages, glial cells, and nerve cells may all po-
tentially contribute to DPN pathogenesis (Fig. 3B). There-
fore, determining the precise localization of ER stress in
peripheral nerve and characterization of UPR pathways in
these cells is necessary to comprehend what role ER stress
plays in DPN. Furthermore, the multitude of physiological
mechanisms that are potentially involved in DPN pathogen-
esis, including hyperglycemia, dyslipidemia, inflammation,
oxidative stress, and altered calcium signaling (Fig. 3A), all
add a level of complexity to studies aimed at understanding
the connections between ER stress and DPN. In this review,
FIG. 3. Mechanisms of diabetic neuropathy. Factors linked to type 1 diabetes (orange), type 2 diabetes (blue), and both
(green) cause DNA damage, ER stress, mitochondrial complex dysfunction, apoptosis, and loss of neurotrophic signaling
(A). This cell damage can occur in neurons, glial cells, and vascular endothelial cells, as well as triggering macro-
phage activation, all of which can lead to nerve dysfunction and neuropathy (B). The relative importance of the pathways in
this network will vary with the cell type, disease profile, and time. AGE, advanced glycation end products; LDL, low-
density lipoprotein; HDL, high-density lipoprotein; FFA, free fatty acids; ROS, reactive oxygen species (red star); PI3K,
phosphatidylinositol-3-kinase; LOX1, oxidized LDL receptor 1; RAGE, receptor for advanced glycation end products;
TLR4, Toll-like receptor 4. Reprinted from: The Lancet Neurology, Vol. 11, Callaghan et al., Diabetic neuropathy: clinical
manifestations and current treatments, Pages 521–534, Copyright (2012), with permission from Elsevier. To see this
illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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we discuss evidence demonstrating how ER stress intersects
with these pathways to provide insight into the possible in-
volvement of ER stress in DPN pathogenesis.
Hyperglycemia
Evidence from studies examining ER stress in diabetic
complications-prone tissues supports the contention that
hyperglycemia can impact ER stress and the integrated stress
response (14, 45). Diabetic retinopathy studies demonstrate
that high-glucose treatment of retinal endothelial cells results
in increased levels of CHOP, ATF4, and phosphorylated
PERK and eIF2a, upregulation of inflammatory cytokines,
including tumor necrosis factor a (TNFa), and increased
expression of vascular endothelial growth factor (VEGF)
(14). This link is further supported by studies demonstrating
improvements in retinal inflammation and vascular leakage
with Atf4 knockdown in STZ-injected mice (14). Markers of
UPR signaling are also significantly upregulated in diabetic
cardiomyopathy. Increased expression of phosphorylated
PERK and eIF2a, ATF4, CHOP, and ATF6 is observed in the
myocardium of spontaneous diabetic Torii rats, a model of
nonobese type 2 diabetes (45). Finally, lipotoxicity-induced
ER stress responses, including decreases in ER calcium
levels and expression of CHOP, XBP1, and BiP/GRP78, are
exacerbated in immortalized Schwann cells (iSCs) in the
presence of high glucose (70); however, glucose exposure in
the absence of lipotoxicity did not affect cell viability or ER
calcium levels. In addition, along these lines, diabetic pa-
tients with DPN who receive intensive glucose therapy do
not show favorable improvements in nerve function (10),
suggesting that glucose-independent processes also contrib-
ute to DPN.
Dyslipidemia
Dyslipidemia is strongly associated with DPN patho-
physiology by both epidemiological and basic research (2,
98, 99, 105), and elevated levels of fatty acid and cholesterol-
induced ER stress have been implicated in metabolic diseases
(37, 46, 50, 65, 89). Therefore, it is important to understand
how abnormal lipid content can provoke ER stress in DPN.
Cell-based approaches have determined that elevated con-
centrations of free fatty acids (FFA) can trigger the UPR in
supporting cells of the peripheral nerve. Using iSCs, inves-
tigators have demonstrated that lipotoxicity associated with
the saturated fatty acid palmitate (PA) promotes iSC dys-
function and cell death via the UPR signaling pathway, as
evidenced by increased expression of BiP, CHOP, and XBP1
(70). These studies also demonstrated that activation of the
UPR precedes the generation of reactive oxygen species
(ROS), mitochondrial depolarization, and apoptosis, sug-
gesting that the ER stress response occurs upstream of these
processes (70). Interestingly, oleate, a monounsaturated fatty
acid, abolishes PA-induced ER stress and lipotoxicity in
C2C12 myoblasts, indicating that the composition of fatty
acid-derived phospholipids within the ER is an important
determinant of UPR activation (72).
Cholesterol has also been implicated in ER stress, as the
ER is incredibly sensitive to perturbations in free cholesterol
levels given its particularly low native cholesterol content
(8). In macrophages, cholesterol loading depletes ER luminal
calcium stores and triggers UPR activation, the expression of
CHOP, and caspase-3-mediated apoptosis (23). Moreover,
unlike esterified cholesterol, the insertion of free cholesterol
into the lipid bilayer of macrophages can cause disturbances
in the physical properties of the membrane, which may in
turn activate the UPR. Along these lines, Schwann cells play
a significant role in myelination and are incredibly sensitive
to perturbation in membrane composition, suggesting that
dyslipidemia-induced ER stress in Schwann cells may play a
role in DPN pathogenesis. ER stress is involved in multiple
myelin-related disorders (16, 51, 73, 83), and recent evidence
has identified abnormalities in the sciatic nerve of STZ-
treated rats that include imbalances in myelin’s phospholipid,
fatty acid, and cholesterol content (13). Thus, an altered lipid
profile brought on by disturbances in lipid homeostasis has
important consequences in Schwann cell biology by affecting
membrane fluidity and function (1, 13). This may be espe-
cially important during remyelination following nerve injury
in diabetes if myelin generation is compromised due to ele-
vated/abnormal lipid substrates. However, the role of lipid
homeostasis and ER stress in DPN remains relatively unex-
plored and further studies addressing this relationship are
warranted.
Insulin signaling
Although hyperglycemia resulting from dysfunctional in-
sulin signaling in pancreatic b cells and metabolically active
tissues is a key contributor to nerve injury in DPN, recent
evidence also suggests that impaired insulin signaling in
peripheral neurons may also be an important factor in nerve
degeneration. The insulin receptor (IR) and insulin receptor
substrate 1 (IRS1) are widely expressed in cell bodies and
axons of peripheral neurons (30, 86, 87), where they are ac-
tivated by insulin to provide vital neurotrophic support to the
nerve (9, 91, 107). In STZ-injected rats, intrathecal low-dose
insulin treatment attenuated DPN-associated reductions in
nerve function and reversed atrophy of myelinated sural
nerve sensory axons (9). Similarly, insulin resistance has
been observed in dorsal root ganglia from db/db type 2 dia-
betic mice (42) and in hypothalamic neurons in response to
PA-induced lipotoxicity (62). Whereas the exact mechanisms
linking ER stress and insulin resistance in peripheral nerves
must still be elucidated, several mechanisms linking ER
stress and hepatic and adipose insulin resistance have been
proposed (24). One theory suggests that UPR signaling di-
rectly suppresses IR signaling through hyperactivation of
JNK and subsequent phosphorylation of IRS1 (39, 62, 93).
Alternatively, induction of lipogenic and glyconeogenic
genes downstream of UPR signaling could result in abnormal
activation of these pathways and ultimately promote insulin
resistance (24). Further studies are required to comprehend
how ER stress contributes to insulin resistance in DPN.
Inflammation
ER stress-induced UPR signaling is associated with the
production of numerous proinflammatory cytokines (50). In
macrophages, excess free cholesterol induces TNFa and
interleukin-6 (IL-6) production via activation of JNK/NFjB
and CHOP, respectively (37, 110). Recent studies also pro-
vide evidence that inflammation-mediated ER stress is im-
portant in Schwann cell-based nerve injury. Studies
investigating spinal cord injury in rats demonstrate that
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upregulation of TNFa, following sciatic nerve crush injury,
effectively triggers the UPR in Schwann cells (61). Along
with increased BiP/GRP78 expression, TNFa induction of
CHOP expression led to Schwann cell apoptosis, demyelin-
ation, and nerve degeneration (61), suggesting that inflam-
matory mediators may play an important role in DPN disease
progression via ER stress pathways. Upregulation of low-
grade inflammation (41, 81) and elevation of cytokines, such
as TNFa (26, 106), in patients with DPN further emphasize
the importance of additional studies focused on determining
whether these inflammatory factors contribute to ER stress-
induced nerve pathology.
Oxidative stress
Oxidative stress is a major mechanism of hyperglycemia-
induced DPN in humans and rodents (97, 99, 102). During
normal cellular metabolism in mitochondria, ROS are formed
as by-products of electron transfer tomolecular oxygen and are
important signaling molecules in biological processes such as
autophagy, phagocytosis, and inflammation (95). However,
increased ROS production and compromised endogenous an-
tioxidant defenses in diabetes lead to oxidative stress, a pro-
oxidant state resulting in injurious oxidation of proteins and
lipids (97, 99, 102). Indeed, hyperglycemia leads to increased
ROS and cellular apoptosis in cultured dorsal root ganglia
neurons (102). Furthermore, the ER is both a source of in-
creased ROS generation and is affected by increased cellular
ROS (4). Although it is less well characterized than in mito-
chondria, the ER has its own electron transport system that
traffics reducing equivalents within the lumen of the ER and
transfers electrons to molecular oxygen, resulting in con-
comitant ROS production (60). Thus, ROS generation is a
natural by-product of ER oxidative protein folding and ac-
counts for *25% of the total cellular ROS generation (92).
Under times of increased protein load, ERROS generation can
significantly increase (60). Given the potential for high levels
of ROS in the cell and ER, oxidative stress may significantly
impact the ER stress response in DPN.
During normal physiological conditions, endogenous an-
tioxidant mechanisms are upregulated to scavenge free rad-
icals and prevent cellular injury (4). During ER stress,
activation of PERK signaling increases NF-E2-related factor
2 (NRF2) activation and subsequent transcription of antiox-
idant and detoxification enzyme genes. This response is ev-
ident in cultured dorsal root ganglion neurons and in
Schwann cells in response to acute hyperglycemic and oxi-
dative (hydrogen peroxide) stress (100). Prolonged hyper-
glycemia, on the other hand, attenuates dorsal root ganglion
neuron antioxidant levels and activities (100), increasing the
significance of ER ROS generation under disease conditions.
Similarly, the glutathione antioxidant activity in the ER is
impacted by oxidative stress. During normal ER protein
folding (4, 60) and during the UPR response to correct mis-
folded proteins (60), glutathione is converted from its re-
duced form (GSH) to an oxidized form (GSSG); however,
excessive UPR activation can deplete the GSH:GSSG ratio,
decreasing its antioxidant capacity. Chronic stress-induced
UPR-mediated CHOP elevation also depletes the glutathione
antioxidant capacity and increases ROS production, further
escalating cellular oxidative stress levels (5, 63). Along these
lines, decreasing ER stress and CHOP expression with
TMAO chaperone protein treatment for 12 weeks following
STZ-induced diabetes in rats attenuates lipid and protein
oxidation in the sciatic nerve, and is coincident with im-
provements in electrophysiological, behavioral, and struc-
tural neuropathy parameters in treated diabetic animals (57).
Further work from the same group using Chop knockout
mice confirmed that a CHOP-mediated ER stress response is
involved in sciatic nerve oxidative stress and the develop-
ment of DPN (57), and is consistent with reports that pan-
creatic b cell CHOP deletion decreases oxidative damage in a
number of mouse models of diabetes (82).
In addition to normal protein folding and the UPR, sources
of ROS outside the ER may also trigger the ER stress re-
sponse (i.e., the mitochondrial respiratory chain, increased
NADPH oxidase activity, and inflammatory processes). Al-
though these sources of ROS in diabetes and their contribu-
tion to peripheral nerve dysfunction are relatively well
characterized, their interactions with the ER remain largely
unexplored (60) and require future attention.
Calcium signaling
The ER is a major store for intracellular calcium, and cal-
cium levels are three- to four-times greater in the ER lumen
than in the cytosol (85); thus, factors that perturb calcium
homeostasis activate the UPR. Experimentally, calcium stores
in the ER can be depleted using the calcium ionophore A23167
or thapsigargin to block uptake of calcium from the cytosol (7,
18). This depletion impairs calcium-dependent chaperones and
folding enzymes and results in the accumulation of misfolded
proteins and subsequent activation of the UPR (11, 27, 75, 84).
Disruptions of ER calcium homeostasis are involved in various
forms of neuropathology (94), and evidence for disrupted ER
calcium homeostasis is evident in diabetic animal models.
Dorsal root ganglia sensory neurons from type 1 diabetic STZ-
injected rats exhibit reduced calcium levels and diminished
calcium uptake by the ER (111). Similarly, comparison of
lumbar and cervical dorsal root ganglia neurons from diabetic
STZ rats revealed that altered calcium dynamics are more
prominent in lumbar neurons, the ganglia that are affected first
in DPN (40, 43). Additional implications for a role of ER
calcium homeostasis in DPN stems from the recent microarray
analysis of peripheral nerve tissue from diabetic mice. Dif-
ferentially expressed genes (DEGs) related to Ca2+ transport
are highly downregulated in 24-week db/db mice; however, no
significant increase is observed in UPR-related DEGs despite
large changes in calcium (71). Experimental validation is re-
quired to confirm these data, but it is plausible that calcium-
induced ER stress may induce UPR-independent cellular
stress. Studies in human and mouse macrophages demonstrate
that ER stress activates the NOD-like receptor family, pyrin
domain containing 3 (NLRP3) inflammasome, and subsequent
inflammatory responses independent of the UPR (64), and
calcium release from the ER can impact mitochondrial
membrane depolarization and increase oxidative stress, which
could contribute to neuronal injury (27). Further examination
into the relationship between calcium signaling in DPN is
required.
Conclusion
Despite recent advances in our understanding of DPN
pathophysiology, few therapies exist for the management of
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DPN. Given the recent association of ER stress with DPN in
diabetic animal models, the association of ER stress with
pathways involved in DPN pathogenesis and the insight
gained from studies examining interventions that target ER
stress pathways, the development of therapeutic approaches
that enhance ER function (i.e., increase chaperone avail-
ability) and decrease UPR-activated cell death should be
considered. The role of ER stress in DPN, however, remains
largely unexplored and several key questions must still be
answered. For instance, what induces ER stress in the diabetic
milieu of the peripheral nerve? What cells in the peripheral
nerve are affected by ER stress, and are all affected cells
equally susceptible to ER stress? Furthermore, which UPR
pathways are implicated in DPN? Finally, what is the inter-
play between ER stress and other components of DPN
pathogenesis, such as calcium storage and transport, oxida-
tive stress, myelination and insulin signaling? As an abun-
dance of information on other signaling pathways in DPN
etiology exists, it is crucial to understand these interactions
with the ER and elucidate how they contribute to disease.
With additional insight into cell-specific contributions of the
UPR to DPN pathogenesis, we hope to ultimately discover
mechanism-based therapies that can prevent this injury cas-
cade and ameliorate the signs and symptoms of DPN.
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Abbreviations Used
AGE¼ advanced glycation end products
ASK1¼ apoptosis signal-regulating kinase 1
ATF4¼ activating transcription factor 4
ATF6¼ activating transcription factor 6
BiP¼ binding immunoglobulin protein
CHOP¼C/EBP homologous protein
DEG¼ differentially expressed gene
DPN¼ diabetic peripheral neuropathy
eIF2a¼ eukaryotic initiation factor 2a
ER¼ endoplasmic reticulum
ERAD¼ER-associated protein degradation
ERO1a¼ER oxidase 1a
FFA¼ free fatty acid
GRP¼ glucose regulating protein
GSH, GSSG¼ glutathione (reduced, oxidized)
HDL¼ high-density lipoprotein
HFD¼ high-fat diet
IL-6¼ interleukin-6
IP3¼ inositol 1,4,5-triphosphate
IR¼ insulin receptor
IRE1a¼ inositol-requiring enzyme 1a
IRS1¼ insulin receptor substrate 1
iSCs¼ immortalized Schwann cells
JNK¼ c-Jun-N-terminal kinase
LCAT¼ lecithin-cholesterol acyltransferase
LDL¼ low-density lipoprotein
LOX1¼ oxidized LDL receptor 1
NLRP3¼NOD-like receptor family, pyrin
domain containing 3
NRF2¼NF-E2-related factor 2
ORP150¼ oxygen regulated protein 150
PA¼ palmitate
PBA¼ phenyl butyric acid
PERK¼ protein kinase-R-like ER kinase
PI3K¼ phosphatidylinositol-3-kinase
RAGE¼ receptor for advanced glycation
end products
ROS¼ reactive oxygen species
STZ¼ streptozotocin
sXBP1¼ spliced X-box binding protein 1
TLR4¼Toll-like receptor 4
TMAO¼ trimethylamine oxide
TNFa¼ tumor necrosis factor a
TRAF2¼ tumor necrosis factor receptor-
associated factor 2
UPR¼ unfolded protein response
XBP1¼X-box binding protein 1
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